Who is sponsoring NCT02903381?

NCT02903381 is sponsored by Dana-Farber Cancer Institute.

What condition does NCT02903381 study?

NCT02903381 studies Smoldering Multiple Myeloma.

What drugs are being tested in NCT02903381?

Interventions: Nivolumab, Lenalidomide, Dexamethasone.

What is the status of NCT02903381?

NCT02903381 is currently COMPLETED.

Last reviewed 2023-06-13 · How we verify

A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma

NCT02903381 PHASE2 COMPLETED Results posted

This research study is evaluating a new drug called "nivolumab" as a possible treatment for smoldering multiple myeloma in order to prevent or postpone development of active multiple myeloma. \- Patients with smoldering multiple myeloma do not have symptoms but are at risk for progressing to active multiple myeloma. Multiple myeloma is a cancer of the plasma cell, which is an important part of the immune system. Patients with active multiple myeloma generally require treatment.

Details

Lead sponsor	Dana-Farber Cancer Institute
Phase	PHASE2
Status	COMPLETED
Enrolment	8
Start date	Thu Oct 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Sep 16 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Smoldering Multiple Myeloma

Interventions

Nivolumab
Lenalidomide
Dexamethasone

Countries

United States